"We found that [this
program] increased prescribing of evidence-based cancer drugs without changing
overall spending. This is a big deal, given how important evidence-based cancer
drug prescribing is to achieving the best possible outcomes in cancer care."
— Justin Bekelman, M.D., director of the Penn Center for Cancer
Care Innovation at the Abramson Cancer Center, spoke with AIS's RADAR on Specialty Pharmacy
about his recent study of Anthem's Cancer Care Quality Program treatment
pathways.
Subscribers may read the RADAR on Specialty Pharmacy article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment